Paclitaxel versus sirolimus stents in diabetic and nondiabetic patients

Circulation: Cardiovascular Quality and Outcomes

Volumn 2, Issue 2, 2009, Pages 96-107

  Chiu, Maria ^a,b   Ko, Dennis T ^a,b   Austin, Peter C ^a   Cohen, Eric A ^a,b   Velianou, James L ^a,b,c   Goeree, Ron ^a,b,c   Blackhouse, Gord ^a   Tu, Jack V ^a  

^a INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

Author keywords

Coronary disease; Diabetes mellitus; Real world outcomes; Revascularization; Stents

Indexed keywords

PACLITAXEL; RAPAMYCIN; IMMUNOSUPPRESSIVE AGENT; TUBULIN MODULATOR;

ADULT; AGED; ARTICLE; BARE METAL STENT; CANADA; CORONARY ARTERY DISEASE; DEATH; DIABETES MELLITUS; DRUG ELUTING STENT; FEMALE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; NORMAL HUMAN; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REVASCULARIZATION; COHORT ANALYSIS; COMPARATIVE STUDY; DIABETIC ANGIOPATHY; DISEASE FREE SURVIVAL; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODEL; REGISTER; STATISTICS; TRANSLUMINAL CORONARY ANGIOPLASTY;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; COHORT STUDIES; CORONARY ARTERY DISEASE; DIABETIC ANGIOPATHIES; DISEASE-FREE SURVIVAL; DRUG-ELUTING STENTS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; ONTARIO; PACLITAXEL; PROPORTIONAL HAZARDS MODELS; REGISTRIES; SIROLIMUS; TUBULIN MODULATORS;

EID: 77949530400     PISSN: 19417713     EISSN: 19417705     Source Type: Journal    
DOI: 10.1161/CIRCOUTCOMES.108.826057     Document Type: Article

References (34)

1. Tu JV, Bowen J, Chiu M, Ko DT, Austin PC, He Y, Hopkins R, Tarride JE, Blackhouse G, Lazzam C, Cohen EA, Goeree R. Effectiveness and safety of drug-eluting stents in Ontario. N Engl J Med. 2007; 357: 1393-1402.
2. Kastrati A, Mehilli J, Pache J, Kaiser C, Valgimigli M, Kelbaek H, Menichelli M, Sabate M, Suttorp MJ, Baumgart D, Seyfarth M, Pfisterer ME, Schomig A. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med. 2007; 356: 1030-1039.
3. Stone GW, Moses JW, Ellis SG, Schofer J, Dawkins KD, Morice MC, Colombo A, Schampaert E, Grube E, Kirtane AJ, Cutlip DE, Fahy M, Pocock SJ, Mehran R, Leon MB. Safety and efficacy of sirolimus-and paclitaxel-eluting coronary stents. N Engl J Med. 2007; 356: 998-1008.
4. Galloe AM, Thuesen L, Kelbaek H, Thayssen P, Rasmussen K, Hansen PR, Bligaard N, Saunamaki K, Junker A, Aaroe J, Abildgaard U, Ravkilde J, Engstrom T, Jensen JS, Andersen HR, Botker HE, Galatius S, Kristensen SD, Madsen JK, Krusell LR, Abildstrom SZ, Stephansen GB, Lassen JF. Comparison of paclitaxel-and sirolimus-eluting stents in everyday clinical practice: the SORT OUT II randomized trial. JAMA. 2008; 299: 409-416.
5. Morice MC, Colombo A, Meier B, Serruys P, Tamburino C, Guagliumi G, Sousa E, Stoll HP. Sirolimus-vs paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial. JAMA. 2006; 295: 895-904.
6. Stettler C, Wandel S, Allemann S, Kastrati A, Morice MC, Schomig A, Pfisterer ME, Stone GW, Leon MB, de Lezo JS, Goy JJ, Park SJ, Sabate M, Suttorp MJ, Kelbaek H, Spaulding C, Menichelli M, Vermeersch P, Dirksen MT, Cervinka P, Petronio AS, Nordmann AJ, Diem P, Meier B, Zwahlen M, Reichenbach S, Trelle S, Windecker S, Juni P. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet. 2007; 370: 937-948. (Pubitemid 47393576)
7. Schomig A, Dibra A, Windecker S, Mehilli J, Suarez dL, Kaiser C, Park SJ, Goy JJ, Lee JH, Di Lorenzo E, Wu J, Juni P, Pfisterer ME, Meier B, Kastrati A. A meta-analysis of 16 randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in patients with coronary artery disease. J Am Coll Cardiol. 2007; 50: 1373-1380.
8. Kastrati A, Dibra A, Eberle S, Mehilli J, Suarez DL, Goy JJ, Ulm K, Schomig A. Sirolimus-eluting stents vs paclitaxel-eluting stents in patients with coronary artery disease: meta-analysis of randomized trials. JAMA. 2005; 294: 819-825.
9. Luscher TF, Creager MA, Beckman JA, Cosentino F. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part II. Circulation. 2003; 108: 1655-1661. (Pubitemid 37187795)
10. Hurst RT, Lee RW. Increased incidence of coronary atherosclerosis in type 2 diabetes mellitus: mechanisms and management. Ann Intern Med. 2003; 139: 824-834.
11. Elezi S, Kastrati A, Pache J, Wehinger A, Hadamitzky M, Dirschinger J, Neumann FJ, Schomig A. Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement. J Am Coll Cardiol. 1998; 32: 1866-1873. (Pubitemid 29010448)
12. Flaherty JD, Davidson CJ. Diabetes and coronary revascularization. JAMA. 2005; 293: 1501-1508.
13. Ko DT, Chiu M, Austin PC, Bowen J, Cohen EA, Tu JV. Safety and effectiveness of drug-eluting stents among diabetics: a propensity analysis. Am Heart J. 2008; 156: 125-134.
14. Dibra A, Kastrati A, Mehilli J, Pache J, Schuhlen H, von Beckerath N, Ulm K, Wessely R, Dirschinger J, Schomig A. Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients. N Engl J Med. 2005; 353: 663-670.
15. Daemen J, Garcia-Garcia HM, Kukreja N, Imani F, de Jaegere PP, Sianos G, van Domburg RT, Serruys PW. The long-term value of sirolimus-and paclitaxel-eluting stents over bare metal stents in patients with diabetes mellitus. Eur Heart J. 2007; 28: 26-32.
16. Stettler C, Allemann S, Egger M, Windecker S, Meier B, Diem P. Efficacy of drug eluting stents in patients with and without diabetes mellitus: indirect comparison of controlled trials. Heart. 2006; 92: 650-657.
17. Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, Saunders LD, Beck CA, Feasby TE, Ghali WA. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005; 43: 1130-1139. (Pubitemid 41587600)
18. Wilkins R. Use of postal codes and addresses in the analysis of health data. Health Rep. 1993; 5: 157-177.
19. Hux JE, Ivis F, Flintoft V, Bica A. Diabetes in Ontario: determination of prevalence and incidence using a validated administrative data algorithm. Diabetes Care. 2002; 25: 512-516. (Pubitemid 41103345)
20. Lipscombe LL, Hux JE. Trends in diabetes prevalence, incidence, and mortality in Ontario, Canada 1995-2005: a population-based study. Lancet. 2007; 369: 750-756.
21. Austin PC, Daly PA, Tu JV. A multicenter study of the coding accuracy of hospital discharge administrative data for patients admitted to cardiac care units in Ontario. Am Heart J. 2002; 144: 290-296.
22. Austin PC, Mamdani MM. A comparison of propensity score methods: a case-study estimating the effectiveness of post-AMI statin use. Stat Med. 2006; 25: 2084-2106.
23. Austin PC. Propensity-score matching in the cardiovascular surgery literature from 2004 to 2006: a systematic review and suggestions for improvement. J Thorac Cardiovasc Surg. 2007; 134: 1128-1135.
24. Austin PC. A critical appraisal of propensity-score matching in the medical literature between 1996 and 2003. Stat Med. 2008; 27: 2037-2049. (Pubitemid 351772300)
25. Austin PC, Grootendorst P, Anderson GM. A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: a Monte Carlo study. Stat Med. 2007;26:734-753. (Pubitemid 46206593)
26. Klein JP, Moeschberger ML. Survival Analysis: Techniques for Censored and Truncated Data. New York: Springer-Verlag; 1997.
27. Carrera AC. TOR signaling in mammals. J Cell Sci. 2004;117:4615-4616.
28. Carter AJ. TOR of the cell cycle: are there important implications for diabetics in the era of the drug-eluting stent? Catheter Cardiovasc Interv. 2004; 61: 233-236.
29. Blagosklonny MV, Darzynkiewicz Z, Halicka HD, Pozarowski P, Demidenko ZN, Barry JJ, Kamath KR, Herrmann RA. Paclitaxel induces primary and postmitotic G1 arrest in human arterial smooth muscle cells. Cell Cycle. 2004; 3: 1050-1056. (Pubitemid 40268664)
30. Axel DI, Kunert W, Goggelmann C, Oberhoff M, Herdeg C, Kuttner A, Wild DH, Brehm BR, Riessen R, Koveker G, Karsch KR. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation. 1997; 96: 636-645. (Pubitemid 27329445)
31. Patterson C, Mapera S, Li HH, Madamanchi N, Hilliard E, Lineberger R, Herrmann R, Charles P. Comparative effects of paclitaxel and rapamycin on smooth muscle migration and survival: role of AKT-dependent signaling. Arterioscler Thromb Vasc Biol. 2006; 26: 1473-1480. (Pubitemid 44288971)
32. Ong AT, Aoki J, van Mieghem CA, Rodriguez Granillo GA, Valgimigli M, Tsuchida K, Sonnenschein K, Regar E, van der Giessen WJ, de Jaegere PP, Sianos G, McFadden EP, de Feyter PJ, van Domburg RT, Serruys PW. Comparison of short-(one month) and long-(twelve months) term outcomes of sirolimus-versus paclitaxel-eluting stents in 293 consecutive patients with diabetes mellitus (from the RESEARCH and T-SEARCH registries). Am J Cardiol. 2005; 96: 358-362. (Pubitemid 41058858)
33. Stankovic G, Cosgrave J, Chieffo A, Iakovou I, Sangiorgi G, Montorfano M, Airoldi F, Carlino M, Michev I, Finci L, Colombo A. Impact of sirolimus-eluting and paclitaxel-eluting stents on outcome in patients with diabetes mellitus and stenting in more than one coronary artery. Am J Cardiol. 2006; 98: 362-366. (Pubitemid 44062445)
34. Billinger M, Beutler J, Taghetchian KR, Remondino A, Wenaweser P, Cook S, Togni M, Seiler C, Stettler C, Eberli FR, Luscher TF, Wandel S, Juni P, Meier B, Windecker S. Two-year clinical outcome after implantation of sirolimus-eluting and paclitaxel-eluting stents in diabetic patients. Eur Heart J. 2008; 29: 718-725. (Pubitemid 351431021)